MDS Announces Formation of Special Committee
02 Februar 2009 - 1:00PM
PR Newswire (US)
TORONTO, Feb. 2 /PRNewswire-FirstCall/ -- MDS Inc. (TSX: MDS; NYSE:
MDZ), a leading provider of products and services to the global
life-sciences markets, today announced that it has constituted a
committee of independent directors to support the Company's
continuing process of reviewing alternatives to improve shareholder
value. With the assistance of management and advisors, the Board of
Directors continuously reviews the performance of MDS, and looks
for options to improve returns to shareholders, including an annual
strategic review. The Board has determined that constituting a
committee to work closely with management and the company's
advisors is now appropriate. The committee is comprised of William
Anderson, Robert Luba, James MacDonald and Gregory Spivy, each of
whom is independent of management. James MacDonald will act as
Chair of the committee. Goldman, Sachs & Co and RBC Capital
Markets are assisting the Company and the Board of Directors as
financial advisors. The focus of the review is on assessing
strategic alternatives. MDS emphasized that there can be no
assurance that this process will result in any specific strategic
or financial transaction - especially given the uncertain market
and economic conditions. No timetable has been set for its
completion. Caution Concerning Forward-Looking Statements This
document contains forward-looking statements. Some forward-looking
statements may be identified by words like "expects",
"anticipates", "plans", "intends", "indicates" or similar
expressions. The statements are not a guarantee of future
performance and are inherently subject to risks and uncertainties.
MDS's actual results could differ materially from those expressed
in the forward-looking statements due to these risks and a number
of other factors, including, but not limited to, successful
implementation of structural changes, including restructuring plans
and acquisitions, technical or manufacturing or distribution
issues, the competitive environment for MDS's products and
services, the degree of market penetration of its products and
services, the ability to secure a reliable supply of raw materials,
the impact of our clients' exercising rights to delay or cancel
certain contracts, the strength of the global economy, the
stability of global equity markets, the availability and cost of
financing, the impact of the movement of the U.S. dollar relative
to other currencies, particularly the Canadian dollar and the euro,
uncertainties associated with critical accounting assumptions and
estimates, and other factors set forth in reports and other
documents filed by MDS with Canadian and U.S. securities regulatory
authorities from time to time, including MDS's quarterly and annual
MD&A, annual information form, and annual report on Form 40-F
for the fiscal year ended October 31, 2008 filed with the U.S.
Securities & Exchange Commission. About MDS MDS Inc. (TSX: MDS;
NYSE: MDZ) is a global life sciences company that provides
market-leading products and services that our customers need for
the development of drugs, and the diagnosis and treatment of
disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS has more than
5,000 highly skilled people in 29 countries. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Inc. CONTACT: MEDIA: Janet Ko, (416) 213-4167,
; INVESTORS: Kim Lee, (416) 213-4721,
Copyright